Reviewed,
UniProtKB/Swiss-Prot Q07817 (BCLX_HUMAN)
Last modified
November 25, 2008.
Version 110.
History...
Clusters with 100%,
90%,
50% identity |
Documents (4) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Apoptosis regulator Bcl-X Alternative name(s): Bcl-2-like 1 protein | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 233 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is not processed. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Potent inhibitor of cell death. Isoform Bcl-X(L) anti-apoptotic activity is inhibited by association with SIVA isoform 1. Inhibits activation of caspases By similarity. Appears to regulate cell death by blocking the voltage-dependent anion channnel (VDAC) by binding to it and preventing the release of the caspase activator, cytochrome c, from the mitochondrial membrane. The Bcl-X(S) isoform promotes apoptosis. |
| Subunit structure | Bcl-X(L) forms homodimers, and heterodimers with BAX, BAK and BCL2. Heterodimerization with BAX does not seem to be required for anti-apoptotic activity. Also interacts with BAD and BBC3. Isoform Bcl-X(L) binds to Siva isoform 1. Interacts with BCL2L11 By similarity. Interacts with BECN1 and PGAM5. |
| Subcellular location | Mitochondrion membrane; Single-pass membrane proteinBy similarity. Nucleus membrane; Single-pass membrane protein; Cytoplasmic sideBy similarity. Note= Mitochondrial membranes and perinuclear envelope By similarity. |
| Tissue specificity | Bcl-X(S) is expressed at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. In contrast, Bcl-X(L) is found in tissues containing long-lived postmitotic cells, such as adult brain. |
| Domain | The BH4 motif is required for anti-apoptotic activity. The BH1 and BH2 motifs are required for both heterodimerization with other Bcl-2 family members and for repression of cell death. |
| Post-translational modification | Proteolytically cleaved by caspases during apoptosis. The cleaved protein, lacking the BH4 motif, has pro-apoptotic activity. |
| Sequence similarities | Belongs to the Bcl-2 family. |
Ontologies
Keywords | |
|---|---|
| Biological process | Apoptosis |
| Cellular component | Membrane Mitochondrion Nucleus |
| Coding sequence diversity | Alternative splicing |
| Domain | Transmembrane |
| Technical term | 3D-structure |
Gene Ontology (GO) | |
| Biological process | negative regulation of survival gene product expression Ref.1 Traceable author statement. Source: ProtInc regulation of mitochondrial membrane permeabilityInferred from direct assay. Source: HGNC regulation of mitochondrial membrane potentialInferred from direct assay. Source: HGNC release of cytochrome c from mitochondriaInferred from direct assay. Source: HGNC |
| Cellular component | integral to membrane Inferred from electronic annotation. Source: UniProtKB-KW mitochondrial outer membraneNon-traceable author statement. Source: UniProtKB nuclear membraneInferred from electronic annotation. Source: UniProtKB-SubCell |
| Molecular function | identical protein binding Inferred from physical interaction. Source: IntAct |
| Complete GO annotation... | |
Binary interactions
Alternative products
| This entry describes 3 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform Bcl-X(L) (identifier: Q07817-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform Bcl-X(S) (identifier: Q07817-2) The sequence of this isoform differs from the canonical sequence as follows: 126-188: Missing. | ||||||
| Isoform Bcl-X(beta) (identifier: Q07817-3) The sequence of this isoform differs from the canonical sequence as follows: 189-233: DTFVELYGNN...VLLGSLFSRK → VRTKPLVCPF...CWVIVGDVDS |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | |||||||||||||||||||||
Molecule processing | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 233 | 233 | Apoptosis regulator Bcl-X | PRO_0000143062 | ||||||||||||||||||||||
Regions | ||||||||||||||||||||||||||
| Transmembrane | 210 – 226 | 17 | Potential | |||||||||||||||||||||||
| Motif | 4 – 24 | 21 | BH4 | |||||||||||||||||||||||
| Motif | 86 – 100 | 15 | BH3 | |||||||||||||||||||||||
| Motif | 129 – 148 | 20 | BH1 | |||||||||||||||||||||||
| Motif | 180 – 195 | 16 | BH2 | |||||||||||||||||||||||
Sites | ||||||||||||||||||||||||||
| Site | 61 – 62 | 2 | Cleavage; by caspase-1 | |||||||||||||||||||||||
Natural variations | ||||||||||||||||||||||||||
| Alternative sequence | 126 – 188 | 63 | Missing in isoform Bcl-X(S). | VSP_000515 | ||||||||||||||||||||||
| Alternative sequence | 189 – 233 | 45 | DTFVE…LFSRK → VRTKPLVCPFSLASGQRSPT ALLLYLFLLCWVIVGDVDS in isoform Bcl-X(beta). | VSP_000516 | ||||||||||||||||||||||
Experimental info | ||||||||||||||||||||||||||
| Mutagenesis | 61 | 1 | D → A: No cleavage by caspase-1 nor by caspase-3 | |||||||||||||||||||||||
| Mutagenesis | 131 – 133 | 3 | FRD → VRA: No heterodimerization with BAX | |||||||||||||||||||||||
| Mutagenesis | 135 – 137 | 3 | VNW → AIL: Loss of anti-apoptotic activity | |||||||||||||||||||||||
| Mutagenesis | 138 – 140 | 3 | GRI → ELN: Loss of anti-apoptotic activity | |||||||||||||||||||||||
| Mutagenesis | 138 | 1 | G → A: No heterodimerization with BAX | |||||||||||||||||||||||
| Mutagenesis | 148 | 1 | G → E: No heterodimerization with BAX | |||||||||||||||||||||||
| Mutagenesis | 156 | 1 | D → A: No effect on caspase-1 cleavage | |||||||||||||||||||||||
| Mutagenesis | 176 | 1 | D → A: No effect on caspase-1 cleavage | |||||||||||||||||||||||
| Mutagenesis | 188 – 189 | 2 | WD → GA: Reduces anti-apoptotic activity by about half | |||||||||||||||||||||||
| Mutagenesis | 189 | 1 | D → A: No effect on caspase-1 cleavage | |||||||||||||||||||||||
| Sequence conflict | 70 | 1 | G → A in CAA80661. Ref.1 | |||||||||||||||||||||||
Secondary structure | ||||||||||||||||||||||||||
Helix Strand Turn | ||||||||||||||||||||||||||
| Helix | 2 – 19 | 18 | ||||||||||||||||||||||||
| Helix | 83 – 100 | 18 | ||||||||||||||||||||||||
| Helix | 106 – 112 | 7 | ||||||||||||||||||||||||
| Helix | 120 – 127 | 8 | ||||||||||||||||||||||||
| Helix | 128 – 131 | 4 | ||||||||||||||||||||||||
| Helix | 137 – 156 | 20 | ||||||||||||||||||||||||
| Helix | 162 – 177 | 16 | ||||||||||||||||||||||||
| Helix | 179 – 184 | 6 | ||||||||||||||||||||||||
| Turn | 185 – 187 | 3 | ||||||||||||||||||||||||
| Helix | 188 – 195 | 8 | ||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death." Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nunez G., Thompson C.B. Cell 74:597-608(1993) [PubMed: 8358789] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS BCL-X(L) AND BCL-X(S)). |
| [2] | Inohara N., Ohta S. Submitted (OCT-1996) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM BCL-X(BETA)). |
| [3] | "Identification of a human cDNA encoding a novel Bcl-x isoform." Ban J., Eckhart L., Weninger W., Mildner M., Tschachler E. Biochem. Biophys. Res. Commun. 248:147-152(1998) [PubMed: 9675101] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BCL-X(BETA)). |
| [4] | "Cloning of human full-length CDSs in BD Creator(TM) system donor vector." Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., Phelan M., Farmer A. Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BCL-X(L)). |
| [5] | "The DNA sequence and comparative analysis of human chromosome 20." Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., Bird C.P., Blakey S.E. Rogers J.Nature 414:865-871(2001) [PubMed: 11780052] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [6] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BCL-X(L)). Tissue: Lung. |
| [7] | "Multiple Bcl-2 family members demonstrate selective dimerizations with Bax." Sedlak T.W., Oltvai Z.N., Yang E., Wang K., Boise L.H., Thompson C.B., Korsmeyer S.J. Proc. Natl. Acad. Sci. U.S.A. 92:7834-7838(1995) [PubMed: 7644501] [Abstract] Cited for: MUTAGENESIS OF GLY-138, HETERODIMERIZATION. |
| [8] | "Bax-independent inhibition of apoptosis by Bcl-XL." Cheng E.H.-Y., Levine B., Boise L.H., Thompson C.B., Hardwick J.M., Korsmeyer S.J. Nature 379:554-556(1996) [PubMed: 8596636] [Abstract] Cited for: MUTAGENESIS OF BH1 AND BH2 MOTIFS. |
| [9] | "Modulation of cell death by Bcl-xL through caspase interaction." Clem R.J., Cheng E.H.-Y., Karp C.L., Kirsch D.G., Ueno K., Takahashi A., Kastan M.B., Griffin D.E., Earnshaw W.C., Veliuona M.A., Hardwick J.M. Proc. Natl. Acad. Sci. U.S.A. 95:554-559(1998) [PubMed: 9435230] [Abstract] Cited for: CLEAVAGE BY CASPASES, MUTAGENESIS OF ASP-61. |
| [10] | "PUMA induces the rapid apoptosis of colorectal cancer cells." Yu J., Zhang L., Hwang P.M., Kinzler K.W., Vogelstein B. Mol. Cell 7:673-682(2001) [PubMed: 11463391] [Abstract] Cited for: INTERACTION WITH BCL2 AND BBC3. |
| [11] | "Siva-1 binds to and inhibits BCL-X(L)-mediated protection against UV radiation-induced apoptosis." Xue L., Chu F., Cheng Y., Sun X., Borthakur A., Ramarao M., Pandey P., Wu M., Schlossman S.F., Prasad K.V.S. Proc. Natl. Acad. Sci. U.S.A. 99:6925-6930(2002) [PubMed: 12011449] [Abstract] Cited for: INTERACTION WITH SIVA. |
| [12] | "PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex." Lo S.-C., Hannink M. J. Biol. Chem. 281:37893-37903(2006) [PubMed: 17046835] [Abstract] Cited for: INTERACTION WITH PGAM5. |
| [13] | "X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death." Muchmore S.W., Sattler M., Liang H., Meadows R.P., Harlan J.E., Yoon H.S., Nettesheim D., Chang B.S., Thompson C.B., Wong S.L., Ng S.L., Fesik S.W. Nature 381:335-341(1996) [PubMed: 8692274] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS), STRUCTURE BY NMR OF 1-209. |
| [14] | "Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis." Sattler M., Liang H., Nettesheim D., Meadows R.P., Harlan J.E., Eberstadt M., Yoon H.S., Shuker S.B., Chang B.S., Minn A.J., Thompson C.B., Fesik S.W. Science 275:983-986(1997) [PubMed: 9020082] [Abstract] Cited for: STRUCTURE BY NMR OF 1-209. |
| [15] | "Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies." Petros A.M., Nettesheim D.G., Wang Y., Olejniczak E.T., Meadows R.P., Mack J., Swift K., Matayoshi E.D., Zhang H., Thompson C.B., Fesik S.W. Protein Sci. 9:2528-2534(2000) [PubMed: 11206074] [Abstract] Cited for: STRUCTURE BY NMR OF 1-209 IN COMPLEX WITH BAD. |
| [16] | "Bcl-XL mutations suppress cellular sensitivity to antimycin A." Manion M.K., O'Neill J.W., Giedt C.D., Kim K.M., Zhang K.Y.Z., Hockenbery D.M. J. Biol. Chem. 279:2159-2165(2004) [PubMed: 14534311] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 1-211. |
| [17] | "An inhibitor of Bcl-2 family proteins induces regression of solid tumours." Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G. Rosenberg S.H.Nature 435:677-681(2005) [PubMed: 15902208] [Abstract] Cited for: STRUCTURE BY NMR OF 1-209. |
| [18] | "BCL-XL dimerization by three-dimensional domain swapping." O'Neill J.W., Manion M.K., Maguire B., Hockenbery D.M. J. Mol. Biol. 356:367-381(2006) [PubMed: 16368107] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (3.45 ANGSTROMS) OF 1-211, SUBUNIT. |
| [19] | "Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein." Oberstein A., Jeffrey P.D., Shi Y. J. Biol. Chem. 282:13123-13132(2007) [PubMed: 17337444] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 83-209 IN COMPLEX WITH BECN1. |
| [20] | "Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL." Bruncko M., Oost T.K., Belli B.A., Ding H., Joseph M.K., Kunzer A., Martineau D., McClellan W.J., Mitten M., Ng S.-C., Nimmer P.M., Oltersdorf T., Park C.-M., Petros A.M., Shoemaker A.R., Song X., Wang X., Wendt M.D. Elmore S.W.J. Med. Chem. 50:641-662(2007) [PubMed: 17256834] [Abstract] Cited for: STRUCTURE BY NMR OF 1-209. |
| + | Additional computationally mapped references. |

Clusters with